Lupin

JUL 28, 2026 · REGULATORY APPROVAL

FDA approval: Sugammadex

U.S. Food and Drug Administration

FDA approval of a generic sugammadex formulation; regulatory action does not itself establish clinical efficacy or comparative benefit.

JUL 27, 2026 · REGULATORY APPROVAL

FDA approval: Diazepam

U.S. Food and Drug Administration

This is an FDA approval action for a generic diazepam injectable formulation; it documents regulatory authorization, not clinical trial evidence or comparative efficacy.

JUN 18, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Pentazocine Hydrochloride AND Naloxone Hydrochloride (REMS)

U.S. Food and Drug Administration

FDA supplemental approval of a pentazocine–naloxone combination tablet with REMS requirements; this is a regulatory action, not a clinical trial, and does not report efficacy or safety data.

MAY 28, 2026 · REGULATORY APPROVAL

FDA approval: Sodium Sulfate, Magnesium Sulfate AND Potassium Chloride

U.S. Food and Drug Administration

FDA approval of a generic bowel preparation combination; regulatory action record without clinical trial data or efficacy comparison.

APR 30, 2026 · REGULATORY APPROVAL

FDA approval: Glycerol Phenylbutyrate

U.S. Food and Drug Administration

FDA approval of glycerol phenylbutyrate oral liquid formulation; this is a regulatory action record without clinical trial data and does not establish efficacy or comparative benefit.